
ISO 17593:2022
ISO 17593:2022 Clinical laboratory testing and in vitro medical devices – Requirements for in vitro monitoring systems for self-testing of oral anticoagulant therapy
CDN $379.00
Description
This document specifies requirements for in vitro measuring systems for self-monitoring of vitamin-K antagonist oral anticoagulation therapy, including performance, quality assurance and user training and procedures for the validation of performance by the intended users under actual and simulated conditions of use.
This document applies solely to prothrombin time measuring systems used by lay persons for monitoring their own vitamin-K antagonist oral anticoagulation therapy, and which report results as international normalized ratios (INR).
This document is applicable to manufacturers of such systems and those other organizations (e.g. regulatory authorities and conformity assessment bodies) having the responsibility for assessing the performance of these systems.
This document is not applicable to:
-    in vitro measuring systems for coagulation quantities assessing vitamin-K antagonist oral anticoagulation therapy used by physicians or healthcare providers;
-    non-vitamin-K antagonist oral anticoagulation therapy (e.g. dabigatran);
-    a comprehensive evaluation of all possible factors that can affect the performance of these systems;
-    the medical aspects of oral-anticoagulation therapy.
Edition
2
Published Date
2022-03-11
Status
PUBLISHED
Pages
53
Format 
Secure PDF
Secure – PDF details
- Save your file locally or view it via a web viewer
- Viewing permissions are restricted exclusively to the purchaser
- Device limits - 3
- Printing – Enabled only to print (1) copy
See more about our Environmental Commitment
Abstract
This document specifies requirements for in vitro measuring systems for self-monitoring of vitamin-K antagonist oral anticoagulation therapy, including performance, quality assurance and user training and procedures for the validation of performance by the intended users under actual and simulated conditions of use.
This document applies solely to prothrombin time measuring systems used by lay persons for monitoring their own vitamin-K antagonist oral anticoagulation therapy, and which report results as international normalized ratios (INR).
This document is applicable to manufacturers of such systems and those other organizations (e.g. regulatory authorities and conformity assessment bodies) having the responsibility for assessing the performance of these systems.
This document is not applicable to:
-    in vitro measuring systems for coagulation quantities assessing vitamin-K antagonist oral anticoagulation therapy used by physicians or healthcare providers;
-    non-vitamin-K antagonist oral anticoagulation therapy (e.g. dabigatran);
-    a comprehensive evaluation of all possible factors that can affect the performance of these systems;
-    the medical aspects of oral-anticoagulation therapy.
Previous Editions
Can’t find what you are looking for?
Please contact us at:
Related Documents
-

ISO 22442:2020 Medical devices utilizing animal tissues and their derivatives – Part 2: Controls on sourcing, collection and handling
CDN $186.00 Add to cart -

ISO 10993:2019 Biological evaluation of medical devices – Part 9: Framework for identification and quantification of potential degradation products
CDN $186.00 Add to cart -

ISO 21726:2019 Biological evaluation of medical devices – Application of the threshold of toxicological concern (TTC) for assessing biocompatibility of medical device constituents
CDN $124.00 Add to cart -

ISO 10993:2015 Biological evaluation of medical devices – Part 33: Guidance on tests to evaluate genotoxicity – Supplement to ISO 10993-3
CDN $336.00 Add to cart







